Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Clinical trial NCT07625527 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07625527
- Sponsor
- Tianjin Medical University Second Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-30
- Primary completion
- 2029-03-30
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.